Yen-Shen Lu

21PUBLICATIONS
155CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHealth and ecological risk assessmentHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jul 06, 2026
2025 Update of the Taiwan Expert Consensus on Hormone Receptor-Positive Metastatic Breast Cancer Management.

|May 26, 2026
Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

|Jan 08, 2026
DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.

Komal Jhaveri, Sherene Loi, Erika Hamilton

|May 09, 2025
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.

Xichun Hu, Qingyuan Zhang, Tao Sun

|Mar 05, 2025
Benefit of adjuvant chemotherapy for T1cN0M0 and selected T1bN0M0 triple-negative breast cancer: a nationwide cancer registry-based study.

Chiao Lo, Dwan-Ying Chang, Yen-Shen Lu

|Sep 12, 2024
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.

Aditya Bardia, Komal Jhaveri, Seock-Ah Im

Pageof 4

Frequent Collaborators

7 joint publications

Seock-Ah Im

5 joint publications

Ching-Hung Lin

4 joint publications

I-Chun Chen

4 joint publications

Shin-Cheh Chen